Rhythm Pharmaceuticals (RYTM) said Wednesday that it has launched weight-loss drug Imcivree in Germany. Imcivree received European Commission approval last...
Rhythm Pharmaceuticals (RYTM) said Wednesday the European Commission approved the expansion of the dosing regimen for its Imcivree drug. The approval...
Rhythm Pharmaceuticals (RYTM) has an average rating of outperform and price targets ranging from $4 to $40, according to analysts polled by Capital IQ. (MT...
Rhythm Pharmaceuticals (RYTM) has an average rating of outperform and price targets ranging from $4 to $40, according to analysts polled by Capital IQ. (MT...
| Address | 222 Berkeley Street Boston, Massachusetts 02116-3748 |
| Phone | +1.857.264.4280 |
| Number of Employees | 54 |
| Recent SEC Filing | 06/16/2022 8-K |
| Chairman, President & Chief Executive Officer | David P. Meeker |
| Chief Financial Officer & Treasurer | Hunter C. Smith |
| Vice President-Medical Affairs | Brieana Buckley |
| Chief Technical Officer | Joseph Shulman |
| Price Open | $4.67 |
| Previous Close | $4.35 |
| 52 Week Range | $3.04 - 21.10 |
| Market Capitalization | $219.2 M |
| Shares Outstanding | 50.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/02/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$3.30 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -3,598.16% |
| Return on Equity | -55.66% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
